The Board of Directors of Morepen Laboratories Limited approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. In the standalone segment, the company reported revenue from operations of ₹484.72 Crores for the quarter ended March 31, 2026, compared to ₹484.16 Crores for the preceding quarter (ended December 31, 2025) and ₹465.85 Crores for the corresponding quarter in the previous year (ended March 31, 2025). The company’s net profit for the quarter was reported at ₹23.50 Crores. A comparative analysis of these financial results is presented in the table below:

*Note: QoQ and YoY profit percentage calculations are based on data from the provided financial results and supporting documents.

Morepen Laboratories Limited, established in 1984, is a prominent player in the Indian pharmaceutical and healthcare industry. The company operates primarily in two segments: the pharmaceutical business, which includes active pharmaceutical ingredients (APIs) and finished dosages, and the medical devices segment, where it is a leader in Point of Care (POC) diagnostics such as glucometers and blood pressure monitors. Throughout 2025, the company focused on expanding its domestic finished dosage market, setting a target to reach ₹1,000 Crore in this business segment within five years. Additionally, Morepen has been actively strengthening its API export footprint, notably securing approvals for Loratadine in China. The company has also pursued innovation in its product pipeline, including receiving regulatory approval to conduct studies for a new fatty liver treatment drug, Resmetirom.